So even if one was to discard the neglible subgroup , this still leaves the EfTi/Keytruda combo addressing 70-80% of the head and neck market globally, with a percentage of this market additionally having no chemo free option.
Keep in mind the worlds best selling drug , (Keytruda) cannot address this entire population of sufferers.
Not to mention the fantastic result in a subgroup with an unmet need , and a great opportunity for AA.
Continues to look very promising for mine , hence my continued accumulation at these basement prices.DYOR
Media, page-47
-
- There are more pages in this discussion • 76 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
-0.005(1.64%) |
Mkt cap ! $436.3M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 31.3¢ | 30.0¢ | $960.6K | 3.161M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 188729 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 46153 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |